JP7018885B2 - 食道癌の検出および治療のための組成物および方法 - Google Patents

食道癌の検出および治療のための組成物および方法 Download PDF

Info

Publication number
JP7018885B2
JP7018885B2 JP2018534930A JP2018534930A JP7018885B2 JP 7018885 B2 JP7018885 B2 JP 7018885B2 JP 2018534930 A JP2018534930 A JP 2018534930A JP 2018534930 A JP2018534930 A JP 2018534930A JP 7018885 B2 JP7018885 B2 JP 7018885B2
Authority
JP
Japan
Prior art keywords
cdr
antibody
progastrin
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018534930A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019505785A (ja
JP2019505785A5 (https=
Inventor
アレクサンドル、プリュール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Progastrine et Cancers SARL
Original Assignee
Progastrine et Cancers SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progastrine et Cancers SARL filed Critical Progastrine et Cancers SARL
Publication of JP2019505785A publication Critical patent/JP2019505785A/ja
Publication of JP2019505785A5 publication Critical patent/JP2019505785A5/ja
Priority to JP2022013712A priority Critical patent/JP7363007B2/ja
Application granted granted Critical
Publication of JP7018885B2 publication Critical patent/JP7018885B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018534930A 2015-12-31 2017-01-02 食道癌の検出および治療のための組成物および方法 Active JP7018885B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022013712A JP7363007B2 (ja) 2015-12-31 2022-01-31 食道癌の検出および治療のための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15307189 2015-12-31
EP15307189.9 2015-12-31
EP16305139 2016-02-05
EP16305139.4 2016-02-05
PCT/EP2017/050037 WO2017114976A1 (en) 2015-12-31 2017-01-02 Compositions and methods for detecting and treating esophageal cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022013712A Division JP7363007B2 (ja) 2015-12-31 2022-01-31 食道癌の検出および治療のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2019505785A JP2019505785A (ja) 2019-02-28
JP2019505785A5 JP2019505785A5 (https=) 2020-02-20
JP7018885B2 true JP7018885B2 (ja) 2022-02-14

Family

ID=57821946

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018534930A Active JP7018885B2 (ja) 2015-12-31 2017-01-02 食道癌の検出および治療のための組成物および方法
JP2022013712A Active JP7363007B2 (ja) 2015-12-31 2022-01-31 食道癌の検出および治療のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022013712A Active JP7363007B2 (ja) 2015-12-31 2022-01-31 食道癌の検出および治療のための組成物および方法

Country Status (14)

Country Link
US (2) US11789021B2 (https=)
EP (2) EP3397967B1 (https=)
JP (2) JP7018885B2 (https=)
KR (2) KR102197478B1 (https=)
CN (1) CN108700589A (https=)
AU (2) AU2017204686B2 (https=)
BR (1) BR112018013272A2 (https=)
CA (2) CA3193481A1 (https=)
EA (1) EA037032B1 (https=)
ES (2) ES3003287T3 (https=)
PL (1) PL3397967T3 (https=)
SG (1) SG11201805263TA (https=)
WO (1) WO2017114976A1 (https=)
ZA (1) ZA201804142B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102167078B1 (ko) * 2019-07-19 2020-10-16 (주)파즈코리아 혈액 샘플 이송 장치

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240018264A1 (en) * 2015-12-31 2024-01-18 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting and treating ovarian cancer
WO2019110662A1 (en) * 2017-12-05 2019-06-13 Progastrine Et Cancers S.À R.L. Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
JP7338128B2 (ja) 2017-12-08 2023-09-05 イー、シー、エス、ビオトラッカー、エス、エー、アール、エル 癌診断における放射性標識プロガストリン
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
EP3759492A1 (en) 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrin as a biomarker for immunotherapy
JP7449640B2 (ja) * 2018-03-13 2024-03-14 クレアティブ マイクロテック インコーポレイテッド 循環細胞を用いて被検者における治療反応及び疾患の進行をモニターする方法
WO2021081498A1 (en) * 2019-10-24 2021-04-29 The Johns Hopkins University Compositions and methods for detecting and treating esophageal cancer
JP7287532B2 (ja) * 2020-08-04 2023-06-06 王子ホールディングス株式会社 トイレットロール

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013516437A (ja) 2010-01-08 2013-05-13 ビオレアリテ 結腸直腸癌を処置するための方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20030021786A1 (en) * 2001-07-09 2003-01-30 Gevas Philip C. Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
DK1794586T3 (da) * 2004-09-22 2013-05-13 Cancer Advances Inc Monoklonale antistoffer til progastrin
JP2009529915A (ja) * 2006-03-20 2009-08-27 ゾーマ テクノロジー リミテッド ガストリン物質に対して特異的なヒト抗体および方法
US7854932B2 (en) * 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
US20110085986A1 (en) 2009-10-13 2011-04-14 Pomila Singh Diagnosis and treatment of epithelial cancers using labeled/conjugated progastrin peptides
US9487582B2 (en) 2010-01-08 2016-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for treating pancreatic cancer
US8900817B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
JP5829672B2 (ja) 2010-03-24 2015-12-09 レ ラボラトワール セルヴィエ 結腸直腸及び胃腸癌の予防
US10533050B2 (en) 2010-07-26 2020-01-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and compositions for liver cancer therapy
FI20145550A7 (fi) * 2014-06-13 2015-12-14 Biohit Oyj Gastriini-17 käyttö biomarkkerina atrofiselle gastriitille ja usealle sen seurauksena kohonneelle riskille
WO2016066671A1 (en) * 2014-10-29 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant cancers using progastrin inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013516437A (ja) 2010-01-08 2013-05-13 ビオレアリテ 結腸直腸癌を処置するための方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pathology & Oncology Research volume 14, pages449-455，2008年

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102167078B1 (ko) * 2019-07-19 2020-10-16 (주)파즈코리아 혈액 샘플 이송 장치

Also Published As

Publication number Publication date
AU2017204686A1 (en) 2018-07-05
AU2017204686B2 (en) 2020-04-30
JP2019505785A (ja) 2019-02-28
JP7363007B2 (ja) 2023-10-18
US11789021B2 (en) 2023-10-17
BR112018013272A2 (en) 2018-12-11
KR102430893B1 (ko) 2022-08-09
CA3009785A1 (en) 2017-07-06
PL3397967T3 (pl) 2021-06-28
KR20210002363A (ko) 2021-01-07
EA037032B1 (ru) 2021-01-28
WO2017114976A1 (en) 2017-07-06
US20240085423A1 (en) 2024-03-14
CA3193481A1 (en) 2017-07-06
KR20180108586A (ko) 2018-10-04
ZA201804142B (en) 2019-11-27
AU2020202296A1 (en) 2020-04-23
EP3397967A1 (en) 2018-11-07
AU2020202296B2 (en) 2022-06-02
CN108700589A (zh) 2018-10-23
KR102197478B1 (ko) 2021-01-04
EP3848709A1 (en) 2021-07-14
US20190011447A1 (en) 2019-01-10
EP3397967B1 (en) 2020-12-30
EP3848709B1 (en) 2024-12-04
EP3848709C0 (en) 2024-12-04
ES3003287T3 (en) 2025-03-10
ES2861587T3 (es) 2021-10-06
EA201891527A1 (ru) 2019-01-31
SG11201805263TA (en) 2018-07-30
JP2022064969A (ja) 2022-04-26

Similar Documents

Publication Publication Date Title
JP7363007B2 (ja) 食道癌の検出および治療のための組成物および方法
JP7279761B2 (ja) 卵巣癌の検出および治療のための組成物および方法
JP7478708B2 (ja) 胃癌の検出および治療のための組成物および方法
US20240018264A1 (en) Compositions and methods for detecting and treating ovarian cancer
EA050261B1 (ru) Способ in vitro диагностики рака яичников и способ мониторинга эффективности его лечения
EA050277B1 (ru) Способ диагностики in vitro рака пищевода и способ мониторинга эффективности его лечения

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20190426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220201

R150 Certificate of patent or registration of utility model

Ref document number: 7018885

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250